Assessing the Effectiveness and Safety of Pericapsular Nerve Group (PENG) Block in Hip Fracture Patients on Antithrombotic Therapy

Launched by ALEXANDRIA UNIVERSITY · Aug 30, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a procedure called the Pericapsular Nerve Group (PENG) block, which is used to help manage pain in patients with hip fractures. The study will focus on whether this pain relief method is effective and safe for patients who are also taking medications to prevent blood clots (called antithrombotic therapy). The trial will involve patients aged 65 and older who have been diagnosed with a hip fracture and are scheduled to have surgery within 48 hours. It’s important that participants can give informed consent, meaning they understand the study and agree to take part.

If you qualify for this trial, you can expect to receive the PENG block under ultrasound guidance, which helps the doctors place the anesthetic in the right spot to relieve pain. However, if you have allergies to local anesthetics or other medical reasons that make the PENG block unsuitable for you, you won't be able to participate. This trial is currently not yet recruiting participants, so there is no need to sign up just yet, but it aims to provide valuable information about improving pain management in older adults with hip fractures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 65 years or older
• • diagnosis of hip fracture
• • scheduled for surgical intervention within 48 hours
• • Informed consent obtained.
• Exclusion Criteria:
• • Allergy to local anesthetics,
• • Contraindications to the PENG block
• • inability to provide informed consent.